Glycopeptides - ProtoKinetix

Drug Profile

Glycopeptides - ProtoKinetix

Alternative Names: AAGP™ molecules

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
  • Developer Imaginative Research Associates; ProtoKinetix; ProtoKinetix - Imaginative Research Associates (JV); University of Alberta; University of British Columbia
  • Class Glycopeptides; Glycoproteins; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Macular degeneration
  • No development reported Inflammation; Ocular inflammation; Skin disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ocular-inflammation in Canada (Topical)
  • 04 Nov 2017 No recent reports of development identified for research development in Inflammation in Canada
  • 04 Nov 2017 No recent reports of development identified for research development in Skin-disorders in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top